Dyes and Pigments 114 (2015) 259-266

Contents lists available at ScienceDirect

Dyes and Pigments

journal homepage: www.elsevier.com/locate/dyepig

Photochemical synthesis of indazolo[3,2-*b*]quinazolines and their redox-switching properties



PIGMENTS

Shi-Chen Li^a, Wei-Fang Jhang^a, Teau-Jiuan Liou^b, Ding-Yah Yang^{a,*}

^a Department of Chemistry, Tunghai University, No. 1727, Sec. 4, Taiwan Boulevard, Xitun District, Taichung 40704, Taiwan
^b Department of Applied English, Chaoyang University of Technology, No. 168, Jifeng E. Rd., Wufeng District, Taichung 41349, Taiwan

ARTICLE INFO

Article history: Received 4 October 2014 Received in revised form 21 November 2014 Accepted 25 November 2014 Available online 3 December 2014

Keywords: Indazolo[3,2-b]quinazoline Redox switch Photochemistry Nitrene Biradical Fluorescence

1. Introduction

Indazoloquinazolines refer to a small family of indazole- and quinazoline-fused heterocycles, including indazolo[2,3-a]quinazolines [1], indazolo[2,3-c]quinazolines [2], and indazolo[3,2-b]quinazolines [3-6] (Fig. 1). The molecular scaffolds of indazoloquinazolines are rarely present in the natural products, but indazoloquinazolinederived compounds have been reported to possess a wide range of biological activities. Some indazolo[2,3-a]quinazoline derivatives [7], for instance, were found to exhibit anti-bacterial activity against Gram-negative bacteria and anti-fungal activity against yeast, whereas indazolo[2,3-c]quinazoline-11-sulfonamide [2] was claimed to possess therapeutic activity against inflammation. Nevertheless, the biological and physical properties of indazolo[3,2b]quinazoline derivatives have not yet been described. In light of the potential biological activity associated with the indazole/ guinazoline-fused molecular structure, we envisage that an efficient preparation of the indazolo[3,2-b]quinazoline derivatives may facilitate the exploration of their properties.

Recently we reported [8] an efficient route for the preparation of indazolo[2,3-*a*]quinoline derivatives from 2-(2-nitrophenyl)-1,2,3,4-tetrahydroquinolines via visible light photoredox catalysis,

ABSTRACT

Several indazolo[3,2-*b*]quinazolines were synthesized in moderate to good yields by exposing 2-(2nitrophenyl)-1,2,3,4-tetrahydroquinazolines to UV light (306 nm) in acetonitrile. The scope, limitation, and possible mechanism of this light-mediated reaction as well as the redox-switching properties of the target compounds were explored. Reduction of the colored indazolo[3,2-*b*]quinazoline with sodium borohydride resulted in a distinct change to colorless and a sharp increase in fluorescence intensity. The reduced product can be swiftly reverted to the original form by 2,3-dichloro-5,6-dicyano-1,4benzoquinone oxidation. The reversible redox-switching between the indazolo[3,2-*b*]quinazoline and its reduced product utilizing chemical reduction and oxidation as two external stimuli with dual output properties; that is, color change and emission variation was reported.

© 2014 Elsevier Ltd. All rights reserved.

as shown in Fig. 2. The successful formation of an indazole functionality via light-mediated cyclization of an *N*-(2-nitrobenzyl)aniline moiety prompted us to examine the possibility of extending this methodology to the preparation of indazoloquinazolines. Herein, we describe our efforts to the facile synthesis of indazolo [3,2-*b*]quinazoline derivatives by exposing 2-(2-nitrophenyl)-1,2,3,4-tetrahydroquinazolines to UV light in acetonitrile. The scope and limitation of this photochemical reaction as well as the properties of the target compounds were investigated.

2. Experimental

2.1. General

Melting points were determined on a Mel-Temp melting point apparatus in open capillaries and are uncorrected. MS were performed on JEOL JMS-SX/SX 102A spectrometer. Single crystal structures were determined by a Bruker AXS SMART-1000 X-ray single-crystal diffractometer. IR spectra were obtained using a 1725XFT-IR spectrophotometer. Absorption spectra were recorded using an HP8453 spectrophotometer. Fluorescence spectra were measured with a Hitachi F-4500 fluorescence spectrophotometer. ¹H and ¹³C NMR spectra were recorded at 300 and 75 MHz on a Varian VXR300 spectrometer as well as 600 and 150 MHz on a Varian Unity Inova 600 spectrometer. Chemical shifts were reported in parts per million on the δ scale relative to an internal



^{*} Corresponding author. Tel.: +886 4 2359 7613; fax: +886 4 2359 0426. *E-mail address:* yang@thu.edu.tw (D.-Y. Yang).



Fig. 1. Structures of indazoloquinazolines.

standard (tetramethylsilane, or appropriate solvent peaks) with coupling constants given in hertz. ¹H NMR multiplicity data are denoted by s (singlet), d (doublet), t (triplet), q (quartet), and m (multiplet). Analytical thin-layer chromatography (TLC) was carried out on Merck silica gel 60G-254 plates (25 mm) and developed with the solvents mentioned. Flash chromatography was performed in columns of various diameters with Merck silica gel (230–400 mesh ASTM 9385 kieselgel 60H) by elution with the solvent systems. The visible light irradiation reaction was performed with a 23 W household fluorescence lamp.

2.2. Calculation of fluorescence quantum yield

Quinine hemisulfate salt monohydrate ($\Phi_f = 0.546$, $\lambda_{max} = 455$ nm in aqueous H₂SO₄) was used as an external standard for the measurement of fluorescence quantum yields of **1b** and **24**. Fluorescence quantum yields were measured by comparing the integrated area under the fluorescence curve for compounds **1b**, **24**, and quinine sulfate dihydrate at equal absorbance at the same excitation wavelength. The quantum yields were corrected for the refractive index of the solvent.

2.3. General procedure for the preparation of compounds 4a - e

To a solution of *o*-aminobenzylamine (**2**, 4.1 mmol) in ethanol (25 mL) was added *o*-nitrobenzaldehydes (**3**, 4.1 mmol) and a catalytic amount of ammonium chloride (0.04 mmol) at room temperature. The resulting mixture was stirred at room temperature for 1-2 h. The precipitate was then filtered and washed with water and hexanes to afford the desired product.

2.3.1. 2-(2-Nitrophenyl)-1,2,3,4-tetrahydroquinazoline (4a)

Yellow solid; yield 95%; $R_f = 0.4$ (20% EtOAc/hexanes); mp 80–81 °C (lit.⁹ 80–81 °C); IR ν_{max} (KBr) 3412, 3319, 1605, 1523, 1484, 1359, 1255, 1110, 1043, 748 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 7.79 (td, J = 8.1, 1.5 Hz, 2H), 7.57 (td, J = 7.8, 1.5 Hz, 1H), 7.45 (td, J = 7.8, 1.5 Hz, 1H), 7.07 (td, J = 7.5, 1.2 Hz, 1H), 6.91 (d, J = 6.9 Hz, 1H), 6.73 (td, J = 7.5, 1.2 Hz, 1H), 6.65 (dd, J = 8.1, 0.9 Hz, 1H), 5.89 (s, 1H), 4.34 (s, 1H), 4.04, 3.73 (ABq, J = 16.5 Hz, 1H each).



Fig. 2. Visible light-mediated preparation of indazolo[2,3-*a*]quinoline.

2.3.2. N,N-dimethyl-3-nitro-4-(1,2,3,4-tetrahydroquinazolin-2-yl) aniline (**4b**)

Yellow solid; yield 97%; $R_f = 0.4$ (40% EtOAc/hexanes); mp 115–116 °C; IR ν_{max} (KBr) 3400, 3332, 2871, 1605, 1531, 1483, 1266, 1071, 738 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 7.57 (d, J = 8.7 Hz, 1H), 7.02–7.11 (m, 2H), 6.91 (d, J = 7.2 Hz, 1H), 6.83 (dd, J = 9.0, 3.0 Hz, 1H), 6.71 (t, J = 7.5 Hz, 1H), 6.61 (d, J = 8.1 Hz, 1H), 5.66 (d, J = 1.8 Hz, 1H), 4.26 (s, 1H), 4.13, 3.85 (ABq, J = 16.5 Hz, 1H each), 3.01 (s, 3H); ¹³C NMR (CDCl₃, 75 MHz) δ 150.1, 150.0, 143.3, 129.1, 127.1, 126.1, 121.9, 121.3, 118.1, 115.4, 115.1, 106.9, 64.4, 45.5, 40.1; HRMS (EI) calcd for C₁₆H₁₈N₄O₂ [M⁺] 298.1430, found 298.1435.

2.3.3. 2-(6-Nitrobenzo[d][1,3]dioxol-5-yl)-1,2,3,4tetrahydroquinazoline (**4c**)

Yellow solid; yield 97%; $R_f = 0.6$ (40% EtOAc/hexanes); mp 104–105 °C; IR ν_{max} (KBr) 3332, 2779, 1716, 1612, 1501, 1478, 1328, 1251, 1036, 929, 751 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 7.39 (s, 1H), 7.07 (t, J = 8.1 Hz, 1H), 6.93 (d, J = 7.5 Hz, 1H), 6.74 (td, J = 7.5, 1.2 Hz, 1H), 6.63 (d, J = 8.1 Hz, 1H), 6.12, 6.10 (ABq, J = 1.2 Hz, 1H each), 5.86 (s, 1H), 4.28 (s, 1H), 4.11, 3.82 (ABq, J = 16.5 Hz, 1H each); ¹³C NMR (CDCl₃, 75 MHz) δ 150.4, 146.7, 143.4, 142.7, 133.1, 126.9, 125.8, 120.5, 116.3, 114.2, 108.0, 105.4, 103.2, 63.1, 43.5; HRMS (EI) calcd for C₁₅H₁₃N₃O₄ [M⁺] 299.0906, found 299.0903.

2.3.4. 2-(4-Bromo-2-nitrophenyl)-1,2,3,4-tetrahydroquinazoline (4d)

Yellow solid; yield 98%; $R_f = 0.4$ (20% EtOAc/hexanes); mp 125–126 °C; IR ν_{max} (KBr) 3412, 3331, 1709, 1606, 1530, 1488, 1364, 1258, 1051, 744 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 7.94 (dd, J = 1.8, 0.9 Hz, 1H), 7.67 (d, J = 1.8 Hz, 2H), 7.08 (t, J = 7.5 Hz, 1H), 6.90 (d, J = 7.2 Hz, 1H), 6.73 (td, J = 7.5, 1.8 Hz, 1H), 6.66 (d, J = 7.8 Hz, 1H), 5.90 (d, J = 3.3 Hz, 1H), 4.32 (s, 1H), 3.96, 3.63 (ABq, J = 16.8 Hz, 1H each); ¹³C NMR (CDCl₃, 75 MHz) δ 149.4, 141.9, 135.3, 135.0, 130.5, 127.5, 127.4, 126.2, 121.9, 121.3, 118.5, 115.2, 63.9, 43.9; HRMS (EI) calcd for C₁₄H₁₂BrN₃O₂ [M⁺] 333.0113, found 333.0117.

2.3.5. 2-(1-Nitronaphthalen-2-yl)-1,2,3,4-tetrahydroquinazoline (**4e**)

Yellow solid; yield 78%; $R_f = 0.4$ (20% EtOAc/hexanes); mp 121–122 °C; IR ν_{max} (KBr) 3414, 3326, 1710, 1609, 1528, 1489, 1263, 1116, 1066, 748 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 8.00 (d, J = 9.0 Hz, 1H), 7.92 (dd, J = 7.2, 2.4 Hz, 1H), 7.79–7.75 (m, 2H), 7.68–7.58 (m, 2H), 7.08 (t, J = 8.7 Hz, 1H), 6.93 (d, J = 7.5 Hz, 1H), 6.75 (td, J = 7.5, 1.2 Hz, 1H), 6.65 (d, J = 8.1 Hz, 1H), 5.62 (d, J = 1.8 Hz, 1H), 4.32 (bs, 1H), 4.16, 3.90 (ABq, J = 16.5 Hz, 1H each); ¹³C NMR (CDCl₃, 150 MHz) δ 147.0, 142.6, 133.6, 131.0, 130.5, 128.8, 128.0, 127.6, 127.4, 126.3, 124.4, 124.0, 121.8, 121.3, 118.7, 115.3, 65.5, 45.4; HRMS (EI) calcd for C₁₈H₁₅N₃O₂ [M⁺] 305.1164, found 305.1160.



Scheme 1. Synthesis of the indazolo[3,2-b]quinazolines 1.

2.4. General procedure for the preparation of compounds **1a–e**, **15**, **17**

Photoreactions were performed in the Rayonet photochemical reactor equipped with 306 nm lamps (8 watts each \times 8). To a solution of **4** (3 \times 10⁻³ M) in acetonitrile (20 mL) was irradiated for 90 min. The solution was then concentrated *in vacuo* and the product was purified by column chromatography (5–20% EtOAc and benzene) to give the product.

2.4.1. Indazolo[3,2-b]quinazoline (1a)

Red solid; yield 86%; $R_f = 0.4$ (20% EtOAc/hexanes); mp 216–217 °C; IR ν_{max} (KBr) 3043, 1711, 1635, 1439, 1361, 1099, 906, 741 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 9.66 (s, 1H), 8.54 (d, J = 8.1 Hz, 1H), 8.22 (d, J = 8.4 Hz, 1H), 7.98 (d, J = 8.7 Hz, 1H), 7.74–7.89 (m, 3H), 7.60 (t, J = 8.1 Hz, 1H), 7.37 (td, J = 8.1, 0.9 Hz, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 153.8, 144.9, 143.8, 131.4, 131.3, 128.4, 126.9, 125.7, 121.9, 119.9, 119.0, 115.1, 112.1; HRMS (EI) calcd for C₁₄H₉N₃ [M⁺] 219.0796, found 219.0790.

2.4.2. N,N-dimethylindazolo[3,2-b]quinazolin-3-amine (1b)

Orange solid; yield 62%; $R_f = 0.4$ (40% EtOAc/hexanes); mp 200 °C (dec.); IR ν_{max} (KBr) 3047, 2900, 1715, 1634, 1435, 1121, 1098, 902, 770 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 9.44 (s, 1H), 8.29 (d, J = 8.7 Hz, 1H), 9.00 (d, J = 8.7 Hz, 1H), 7.87 (d, J = 8.7 Hz, 1H), 7.72 (td, J = 8.1, 1.8 Hz, 1H), 7.48 (t, J = 8.1 Hz, 1H), 6.93 (dd, J = 9.0 Hz, 1H), 6.84 (d, J = 2.1 Hz, 1H), 3.15 (s, 6H); ¹³C NMR (CDCl₃, 75 MHz) δ 156.6, 153.5, 145.3, 143.7, 130.9, 129.8, 127.8, 125.8, 125.7, 122.4, 118.1, 109.9, 103.5, 92.6, 40.7; HRMS (EI) calcd for C₁₆H₁₄N₄ [M⁺] 262.1218, found 262.1213.

2.4.3. [1,3]Dioxolo[4',5':5,6]indazolo[3,2-b]quinazoline (1c)

Red solid; yield 84%; $R_f = 0.6$ (40% EtOAc/hexanes); mp 256–257 °C; IR ν_{max} (KBr) 3050, 2910, 1708, 1649, 1492, 1449, 1365, 1301, 1188, 1108, 1042, 954 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 8.10 (dd, J = 9.0, 0.9 Hz, 1H), 7.90 (d, J = 8.4 Hz, 1H), 7.72–7.78 (m, 2H), 7.51 (td, J = 7.8, 1.2 Hz, 1H), 7.18 (d, J = 0.6 Hz, 1H), 6.12 (s, 2H); ¹³C NMR (CDCl₃, 75 MHz) δ 152.7, 151.8, 144.3, 144.1, 143.9, 131.3, 130.9, 128.1, 126.1, 125.8, 118.0, 105.7, 101.6, 97.8, 93.3; HRMS (EI) calcd for C₁₅H₉N₃O₂ [M⁺] 263.0695, found 263.0698.

2.4.4. 3-Bromoindazolo[3,2-b]quinazoline (1d)

Orange solid; yield 65%; $R_f = 0.4$ (20% EtOAc/hexanes); mp 262–263 °C; IR ν_{max} (KBr) 3044, 1713, 1634, 1425, 1366, 1106, 1038, 918, 745 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 9.64 (s, 1H), 8.36 (d, J = 8.7 Hz, 1H), 8.21 (d, J = 8.7 Hz, 1H), 8.01–7.98 (m, 2H), 7.85 (td, J = 7.8, 1.5 Hz, 1H), 7.64 (t, J = 7.8 Hz, 1H), 7.42 (dd, J = 8.7, 1.8 Hz, 1H); ¹³C NMR (CDCl₃, 150 MHz) δ 154.4, 144.7, 144.3, 131.9, 131.3, 128.4, 127.2, 125.91, 125.86, 123.4, 123.0, 119.1, 117.7, 110.9; HRMS (EI) calcd for C₁₄H₈BrN₃ [M⁺] 296.9902, found 296.9908.

2.4.5. Benzo[6,7]indazolo[3,2-b]quinazoline (1e)

Red solid; yield 62%; $R_f = 0.5$ (20% EtOAc/hexanes); mp 264–265 °C; IR ν_{max} (KBr) 3033, 1711, 1614, 1422, 1395, 1325, 1110, 745 cm⁻¹; ¹H NMR (C₆D₆, 600 MHz) δ 9.28 (d, J = 7.8 Hz, 1H), 8.80 (s, 1H), 8.52 (d, J = 8.4 Hz, 1H), 8.07 (d, J = 8.4 Hz, 1H), 7.80 (d, J = 7.8 Hz, 1H), 7.52 (t, J = 7.2 Hz, 1H), 7.47 (d, J = 7.8 Hz, 1H), 7.45 (t, J = 7.2 Hz, 1H), 7.18–7.10 (m, 1H), 6.96 (d, J = 8.4 Hz, 1H), 6.86 (t, J = 6.6 Hz, 1H); ¹³C NMR (C₆D₆, 150 MHz) δ 153.4, 145.2, 145.1, 135.6, 131.9, 131.0, 130.3, 128.9, 128.3, 126.4, 126.2, 125.3, 124.8, 123.9,



Fig. 3. Structures of the prepared **1a**–**e**.



Fig. 4. X-ray crystal structure of 1a.

121.6, 119.2, 118.0, 108.0; HRMS (EI) calcd for $C_{18}H_{11}N_3\ [M^+]$ 269.0953, found 269.0959.

2.4.6. N-(2-carbamoylphenyl)-6-nitrosobenzo[d][1,3]dioxole-5-carboxamide (**15**)

Dark green solid; yield 84%; $R_f = 0.6$ (40% EtOAc/hexanes); mp 162–163 °C; IR ν_{max} (KBr) 3249, 1694, 1583, 1465, 1364, 1281, 1090, 1021, 920, 769 cm⁻¹; ¹H NMR (DMSO- d_6 , 300 MHz) δ 13.00 (s, 1H), 8.19 (dd, J = 8.1, 1.5 Hz, 1H), 7.87 (td, J = 8.1, 1.5 Hz, 1H), 7.75 (d, J = 7.5 Hz, 1H), 7.65 (s, 1H), 7.58 (td, J = 8.1, 1.2 Hz, 1H), 6.31 (s, 2H), 6.14 (s, 1H); ¹³C NMR (DMSO- d_6 , 150 MHz) δ 198.5, 191.6, 189.9, 187.6, 186.0, 176.4, 172.1, 165.0, 164.6, 163.3, 158.7, 147.1, 141.4, 124.6; HRMS (EI) calcd for C₁₅H₁₁N₃O₅ [M⁺] 313.0699, found 313.0691.

2.4.7. 3-Methyl-2-(6-nitrosobenzo[d][1,3]dioxol-5-yl)quinazolin-4(3H)-one (**17**)

Light green solid; yield 85%; $R_f = 0.3$ (20% EtOAc/hexanes); mp 226–227 °C; IR v_{max} (KBr) 1674, 1567, 1472, 1346, 1265, 1068, 1014, 921, 771 cm⁻¹; ¹H NMR (DMSO- d_6 , 300 MHz) δ 8.23 (dd, J = 8.1, 1.5 Hz, 1H), 7.86 (ddd, J = 8.7, 7.2, 1.5 Hz, 1H), 7.70–7.65 (m, 3H), 7.60 (ddd, J = 8.1, 7.2, 1.2 Hz, 1H), 6.33 (s, 2H), 3.32 (s, 3H); ¹³C NMR (DMSO- d_6 , 150 MHz) δ 198.5, 198.4, 192.5, 191.3, 187.5, 184.3, 177.0, 172.0, 164.8, 164.6, 163.6, 158.0, 146.4, 141.6, 126.0, 70.7; HRMS (EI) calcd for C₁₆H₁₁N₃O₄ [M⁺] 309.0750, found 309.0755.

2.5. Preparation of compounds 12, 6, 16, 21, 23, 24

2.5.1. 2-(6-Nitrobenzo[d][1,3]dioxol-5-yl)-2,3-dihydroquinazolin-4(1H)-one (**12**)

To a solution of 2-aminobenzamide (**13**, 500 mg, 3.67 mmol) in ethanol (25 mL) was added 6-nitrobenzo[d][1,3]dioxole-5-carbaldehyde (**14**, 716.5 mg, 3.67 mmol) and a catalytic amount of ammonium chloride (0.18 mmol) at room temperature. The



Fig. 5. X-ray crystal structures of 4a and 6.

resulting mixture was refluxed for 2 h. After cooled down to room temperature, the precipitate was filtered, and washed with water and hexanes to give a yellow solid; 91%, $R_f = 0.4$ (40% EtOAc/hexanes); mp 192–193 °C; IR ν_{max} (KBr) 3410, 3327, 2901, 1655, 1481, 1261, 1034, 879, 748 cm⁻¹; ¹H NMR (DMSO- d_6 , 300 MHz) δ 8.16 (s, 1H), 7.69 (s, 1H), 7.63 (dd, J = 8.1, 1.8 Hz, 1H), 7.25 (td, J = 8.1, 1.5 Hz, 1H), 7.21 (s, 1H), 6.93 (s, 1H), 6.77 (d, J = 7.5 Hz, 1H), 6.71 (td, J = 8.1, 1.2 Hz, 1H), 6.30 (t, J = 2.1 Hz, 1H), 6.25, 6.22 (ABq, J = 0.9 Hz, 1H each); ¹³C NMR (DMSO- d_6 , 150 MHz) δ 163.8, 152.2, 148.2, 147.7, 142.2, 134.0, 133.5, 127.7, 118.1, 115.2, 114.8, 107.6, 105.6, 104.1, 62.8; HRMS (EI) calcd for C₁₅H₁₁N₃O₅ [M⁺] 313.0699, found 313.0694.

2.5.2. 3-Methyl-2-(2-nitrophenyl)-1,2,3,4-tetrahydroquinazoline (**6**)

To a solution of 4a (100 mg, 0.39 mmol) in methylene chloride (10 mL) was added triethylamine (39.4 mg, 0.39 mmol) and methyl iodide (111 mg, 0.47 mmol) at room temperature. The resulting mixture was stirred at that temperature for 2 h. After completion of the reaction, water (30 mL) was added to guench the reaction. The product was then extracted with methylene chloride (20 mL) twice, and the combined organic phase was dried over MgSO₄, filtered, and concentrated in vacuo. The residue was purified by column chromatography to give a yellow solid; yield 88%; $R_f = 0.5$ (20%) EtOAc/hexanes); mp 56–57 °C; IR v_{max} (KBr) 3429, 2865, 1709, 1606, 1520, 1356, 1263, 1056, 834, 748 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 7.74 (dd, J = 6.6, 1.5 Hz, 1H), 7.67 (d, J = 7.8 Hz, 1H), 7.47 (td, *J* = 7.5, 1.5 Hz, 1H), 7.39 (td, *J* = 7.2, 1.5 Hz, 1H), 7.09 (t, *J* = 8.4 Hz, 1H), 8.85 (d, *J* = 7.5 Hz, 1H), 6.72–6.67 (m, 2H), 5.71 (d, *J* = 4.2 Hz, 1H), 4.38 (bs, 1H), 3.54, 3.37 (ABq, *J* = 17.4 Hz, 1H each), 2.39 (s, 3H); ¹³C NMR (CDCl₃, 150 MHz) δ 149.1, 140.8, 136.7, 132.0, 129.0, 128.5, 127.6, 127.5, 124.5, 118.4, 118.0, 113.8, 69.5, 49.7, 41.5; HRMS (EI) calcd for C₁₅H₁₅N₃O₂ [M⁺] 269.1164, found 269.1159.



Scheme 2. Proposed mechanism of the formation of 1a from 4a.



Scheme 3. Synthesis of 15 and 17.

2.5.3. 3-Methyl-2-(6-nitrobenzo[d][1,3]dioxol-5-yl)-2,3dihydroquinazolin-4(1H)-one (**16**)

To a solution of 12 (100 mg, 0.32 mmol) in THF (10 mL) was added sodium hydroxide (64 mg, 1.6 mmol) and methyl iodide (54 mg, 0.38 mmol) at room temperature. The resulting mixture was stirred at that temperature for 1 h. After completion of the reaction, the solution was concentrated and the residue was neutralized by hydrochloric acid to pH about 6. The product was then extracted with ethyl acetate (20 mL) twice, and the combined organic phase was dried over MgSO₄, filtered, and concentrated in vacuo. The residue was purified by column chromatography to give a yellow solid; yield 80%; $R_f = 0.5$ (40%) EtOAc/hexanes); mp 211–212 °C; IR v_{max} (KBr) 3386, 2924, 1737, 1608, 1498, 1260, 1039, 883, 753 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 7.95 (d, J = 7.8 Hz, 1H), 7.61 (s, 1H), 7.26–7.22 (m, 2H), 6.82 (t, J = 7.5 Hz, 1H), 6.77 (s, 1H), 6.50 (d, J = 8.1 Hz, 1H), 6.27 (d, *J* = 2.1 Hz, 1H), 6.13, 6.07 (ABq, *J* = 18.6 Hz, 1H each), 5.39 (s, 1H), 3.01 (s, 3H) ¹³C NMR (CDCl₃, 150 MHz) δ 163.6, 153.2, 148.3, 144.0, 141.8, 133.9, 132.7, 128.4, 119.0, 114.5, 114.3, 106.6, 106.5, 103.4, 69.4, 33.2; HRMS (EI) calcd for C₁₆H₁₃N₃O₅ [M⁺] 327.0855, found 327.0849.

2.5.4. 5-(2-Hydroxyethyl)-5H-indazolo[3,2-b]quinazolin-6-ium (23)

To a solution of **1a** (100 mg, 0.46 mmol) in toluene (5 mL) was added 2-bromoethanol (85.7 mg, 0.69 mmol) at room temperature. The resulting mixture was refluxed for 2 days. After cooled down to room temperature, the precipitate was filtered, and washed with ethyl acetate and hexanes to give a pink solid. To this solid was added water (10 mL) and triethylamine to adjust the pH of the solution to 8. The crude product was then extracted with ethyl acetate (20 mL) twice, and the combined organic phase was dried over MgSO₄, filtered, and concentrated in vacuo. The residue was purified by column chromatography to give a yellow solid; yield 45%; $R_f = 0.5$ (40% EtOAc/hexanes); mp 81–83 °C; IR ν_{max} (KBr) 3178, 2946, 2351, 1739, 1599, 1451, 1343, 1187, 893, 736 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 11.10 (s, 1H), 9.98 (s, 1H), 8.32 (d, I = 8.7 Hz, 1H), 7.80 (dt, I = 8.4, 1.2 Hz, 1H), 7.64 (dd, I = 7.8, 1.5 Hz, 1H), 7.57 (ddd, *J* = 9.0, 7.8, 1.8 Hz, 1H), 7.44 (ddd, *J* = 8.7, 6.6, 1.2 Hz, 1H), 7.36 (d, J = 8.4 Hz, 1H), 7.16 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 6.98 (td, J = 7.8, 0.9 Hz, 1H), 4.43 (t, J = 5.1 Hz, 2H), 4.14 (q, J = 6.0 Hz, 2H),2.84 (t, I = 6.3 Hz, 1H); ¹³C NMR (CDCl₃, 150 MHz) δ 194.9, 145.1, 143.0, 140.6, 136.3, 136.2, 127.7, 119.9, 119.7, 119.4, 118.5, 116.1, 116.0,



Scheme 4. Proposed mechanism for the formation of 15 from 12.

108.7, 62.1, 50.3; HRMS (EI) calcd for $C_{16}H_{15}N_3O_2\ [M^+]$ 281.1164, found 281.1165.

2.5.5. N,N-dimethyl-7,12-dihydroindazolo[3,2-b]quinazolin-3-amine (24)

To a solution of **1b** (100 mg, 0.46 mmol) in methanol (10 mL) was added sodium borohydride (1.9 mg, 0.05 mmol) in one portion at room temperature. After completion of the reaction within 5 min, the solvent was concentrated *in vacuo*. This mixture was poured into water. The product was then extracted twice with methylene chloride to give a white solid, yield 99%; $R_f = 0.3$ (40% EtOAc/hexanes); mp 227–229 °C; IR ν_{max} (KBr) 2854, 1709, 1636, 1494, 1363, 1264, 1157, 873, 751 cm⁻¹; ¹H NMR (CD₃OD, 300 MHz) δ 7.51 (dd, J = 9.3, 0.9 Hz, 1H), 7.24–7.19 (m, 2H), 6.99–6.93 (m, 2H), 6.70 (dd, J = 9.0, 2.1 Hz, 1H), 6.45 (d, J = 2.1 Hz, 1H), 5.44 (s, 2H), 2.95 (s, 6H); ¹³C NMR (CD₃OD, 75 MHz) δ 151.52, 151.51, 136.7, 135.8, 129.3, 128.1, 122.2, 121.1, 115.9, 115.5, 112.1, 102.4, 94.6, 49.5, 41.6; HRMS (EI) calcd for C₁₆H₁₆N₄ [M⁺] 264.1375, found 264.1369.

2.6. DDQ oxidation of compound 24

2.6.1. N,N-dimethylindazolo[3,2-b]quinazolin-3-amine (1b)

To a solution of **24** (66.0, 0.25 mmol) in methylene chloride (10 mL) was added DDQ (61.0, 0.27 mmol) in one portion at room temperature. After completion of the reaction within 30 min, the solvent was concentrated *in vacuo*. This mixture was poured into water. The product was then extracted twice with methylene chloride. The resulting solid was recrystallized from methylene chloride/hexane to give an orange red solid of **1b** quantitatively.

3. Results and discussion

Scheme 1 shows the two-step synthesis of the indazolo[3,2-b] quinazolines 1. The sequence commenced with NH₄Cl-promoted condensation of *o*-aminobenzylamine (2) and *o*-nitrobenzaldehydes (3) to yield the tetrahydroquinazolines 4 [9–11]. The subsequent UV irradiation of **4** under aerobic conditions in acetonitrile afforded the target compounds 1. Note that the formation of the indazolo[2,3-a]quinazolines 5 was not observed. Fig. 3 lists the structures and yields (from 4) of the prepared compounds 1a-e. The molecular structures of 1a-e were verified by ¹H and ¹³C NMR spectroscopy. Among all proton NMR spectra, a characteristic singlet absorption peak appearing at chemical shift of 9.66–9.44 ppm was observed and assigned to the C-7 hydrogen of the indazolo[3,2-b]quinazoline moiety (see 1 in Scheme 1 for atomnumbering). The structure of 1a (R = H, CCDC-980236) was further confirmed by single-crystal X-ray diffraction analysis as shown in Fig. 4, explicitly revealing an indazole/quinazoline-fused molecular skeleton.

Scheme 2 depicts the proposed mechanism of the formation of **1a** from **4a** via UV irradiation (306 nm). Presumably, it begins with photoinduced intramolecular electron transfer from the benzylamine nitrogen atom to the *o*-nitrophenyl group of **4a** to yield the biradical species **7**. Compound **7** further undergoes intramolecular proton transfer from the amine hydrogen atom to the adjacent *ortho* nitro oxygen to give the nitrene **8**. The subsequent *N*–*N* bond formation between nitrene nitrogen and nitrogen atom of the protonated nitro group of **8** furnishes the *N*oxide **9** which is then dehydrated to the aromatized indazole *N*oxide **10** via 1,4-elimination. Final light-mediated deoxygenation of **10** affords the 7,12-dihydroindazolo[3,2-*b*]quinazoline (**11**) which is then oxidized *in situ* by molecular oxygen to give the target compound **1a**.

Fig. 5 shows the X-ray crystal structures of **4a** (CCDC-980238) and **6** (CCDC-980239). The former reveals that the 1,2,3,4-



Fig. 6. X-ray crystal structures of 15 and 17.

tetrahydropyrimidine moiety adopted the envelope-like conformation with the benzylamine nitrogen (N-3) atom protruding from the plane. The o-nitrophenyl group of 4a was found to be situated at the axial position of the envelope-like ring with the nitro group anti to the aniline nitrogen (N-1) and syn to the benzylamine nitrogen (*N*-3). This observation might explain the exclusive formation of **1** in preference to **5** upon UV irradiation of **4** since the benzylamine nitrogen atom is closer to the o-nitro group to facilitate the photoinduced electron transfer (the distance between the two nitrogen atoms was measured to be only 2.928 Å). Conversely, no photogenerated product was observed upon UV irradiation of the *N*-3-methylated **6** (Scheme 1), indicating that **6** is insensitive to the applied irradiation conditions. Apparently, the extra methyl group attached to the N-3 nitrogen blocks the indazole formation between the benzylamine and nitro group but fails to facilitate the indazole formation between N-1 nitrogen and nitro group, presumably due to the fact that the distance between the N-1 nitrogen and the o-nitrophenyl group remain the same after N-3 methylation (Fig. 5). Therefore, no photochemical reaction of 6 was observed.

To further explore the scope and limitation of this photoreaction, compound **12** with a carbonyl group incorporated at the 4position of the quinazoline ring was prepared and subsequently subjected to UV irradiation. Scheme 3 shows the synthesis of **12**, which was prepared by condensation of 2-aminobenzamide (**13**) and 6-nitrobenzo[*d*][1,3]dioxole-5-carbaldehyde (**14**) in the presence of NH₄Cl in ethanol under conditions [**12**]. Upon irradiation of **12** in acetonitrile, the major product isolated was the unexpected *o*nitrosobenzamide **15**, rather than the desired indazolo[3,2-*b*]quinazolin-7(12*H*)-one. Scheme 4 depicts the proposed mechanism for



Scheme 5. Synthesis of compound 23.



Fig. 7. X-ray crystal structure of 23.

the formation of the o-nitrosobenzamide 15 from 12. It presumably begins with light-induced hydrogen transfer from the benzylic hydrogen to nitro group to give the biradical species 18, which may undergo electron delocalization to the structure 19. The nucleophilic attack from the nitro oxygen to the benzylic carbon of 19 yields the benzo[c]isoxazol-1(3H)-ol **20**. The subsequent ring opening of the isoxazolidine ring of 20 gives the 2-hydroxy-2,3dihydroquinazolin-4(1H)-one **21**. Final ring opening of 2-hydroxy-2,3-dihydroquinazolin-4(1H)-one moiety of **21** to expel the amide leaving group affords the product o-nitrosobenzamide 15. A similar photoconversion of o-nitrophenyl imine to the corresponding onitrosobenzamide has been previously reported [13]. Interestingly, when the amide nitrogen of **12** was selectively methylated by methyl iodide in the presence of NaOH as a base in THF (Scheme 3), the resulting *N*-methylated **16** was converted to the nitrosophenyl imine 17 rather than undergoing ring opening reaction upon irradiation. The molecular structures of both 15 (CCDC-980240) and 17 (CCDC-980241) were confirmed by the X-ray crystal crystallography as presented in Fig. 6.

With the availability of compounds 1a-e, we then focused our attention on their chemical properties. Upon alkylation of the *N*-5 position of 1a by 2-bromoethanol in toluene under reflux, the resulting proposed *N*-5 alkylated 22 was found to be highly susceptible to base-mediated hydrolysis to afford the ring-opened 1*H*indazol-3-amine 23 (Scheme 5). The structure of 23 (CCDC-980242)



Fig. 8. UV–vis spectra of $1b~(3.0 \times 10^{-5}~\text{M}$ in MeOH) prior to and after NaBH_4 reduction.



Scheme 6. Redox switch between 1b and 24.

was confirmed by single-crystal X-ray diffraction analysis as presented in Fig. 7.

The formation of the hydrolyzed 23 implies that 1a, in the presence of a suitable nucleophile, is susceptible to 1,4-addition at the C-7 position of the indazolo[3,2-*b*]guinazoline moiety. Indeed, when treated with NaBH₄ in methanol, the orange **1b** was instantly converted to the colorless 24. The reduced 24 can be reverted back to **1b** upon 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) oxidation, Fig. 8 shows the UV-vis absorption spectra of 1b prior to and after NaBH₄ reduction in methanol. It displays two intense bands at 252 and 346 nm, and two shoulder bands at 295 and 334 nm, along with a long wavelength broad absorption with maximum at 465 nm before reduction. Presumably, the broad band at 465 nm is attributed to the increased π delocalization of the chromophore. The reduction of 1b to the indazole 24 resulted in the complete disappearance of the long-wavelength absorbance (465 nm) and the appearance of a short-wavelength band at around 326 nm, which resembles the absorption behavior of N,N-dimethylamino substituted indazole moiety.

Scheme 6 depicts the proposed redox switch between *N*,*N*-dimethylindazolo[3,2-*b*]quinazolin-3-amine (**1b**) and 7,12-dihydroindazolo[3,2-*b*]quinazoline (**24**). In addition to color change, compound **1b** also exhibited a variation in emission as a second output property upon reduction. Fig. 9 shows the emission spectra of **1b** prior to and after NaBH₄ reduction. While compound **1b** was essentially non-fluorescent in acetonitrile ($\Phi_f = 0.007$), the fluorescence intensity at 455 nm increased substantially after reduction, presumably due to the *N*,*N*-dimethylamino substituted indazole fluorophore of **24**. The reduced **24** is highly fluorescent in acetonitrile ($\Phi_f = 0.64$) with up to a 91-fold increase in fluorescence quantum yield after reduction.



Fig. 9. Emission spectra of 1b (3.0 \times 10^{-5} M in MeOH) prior to and after NaBH_4 reduction.

4. Conclusions

In summary, we have developed an efficient route for the construction of indazolo[3,2-*b*]quinazoline skeleton by exposing readily available 2-(2-nitrophenyl)-1,2,3,4-tetrahydroquinazolines to UV light. The prepared compounds were shown to exhibit redox-switching behavior with color change and emission variation as two easily detectable output properties. Further evaluation of their potential to function as materials for organic thin film transistors is currently in progress.

Acknowledgments

The authors thank the National Science Council Taiwan, for financially supporting this research under Contract No. NSC 102-2113-M-029-004-MY2.

Appendix A. Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.dyepig.2014.11.020.

References

 Katayama H, Kato O, Kaneko K. New entry to indazolo[2,3-a]quinazolines by revision of the reported structure of an indolo[1,2-b]indazole derivative. Chem Pharm Bull 1996;44:1099.

- [2] Bell, S. U. S. patent 3,505,315, 5,7-Dihydro-6-oxo-6h-indazolo(2,3-d)(1,4) benzodiazepines-12-sulfonamides. Chem Abstr 1970, 72, 132808r.
- [3] Stevens MFG. Triazines and related products. Part I. 1,3-di-O-cyanophenyltriazene. J Chem Soc C 1967:1096.
- [4] Stevens HNE, Stevens MFG. Triazines and related products. Part IV. Methylation of 3-aryl-3,4-dihydro-4-imino-1,2,3-benzotriazines. J Chem Soc C 1970: 2284.
- [5] Stevens HNE, Stevens MFG. Triazines and related products. Part V. The structure of some red N-alkyl-1,2,3-benzotriazines. J Chem Soc C 1970:2298.
- [6] Gescher A, Stevens MFG, Turnbull CP. Triazines and related products. Part 18. Decomposition of 1,2,3-benzotriazines and related triazenes with sodium azide in acetic acid: a convenient route to azidoarenes. J Chem Soc Perkin Trans 1977;1:103.
- [7] Yakaiah T, Lingaiah BPV, Narsaiah B, Pranaykumar K, Murthy USN. GdCl₃ catalysed Grieco condensation: a facile approach for the synthesis of novel pyrimidine and annulated pyrimidine fused indazole derivatives in single pot under mild conditions and their anti-microbial activity. Eur J Med Chem 2008;43:341.
- [8] Lin WC, Yang DY. Visible light photoredox catalysis: synthesis of indazolo[2,3a]quinolines from 2-(2-nitrophenyl)-1,2,3,4-tetrahydroquinolines. Org Lett 2013;15:4862.
- [9] Correa WH, Papadopoulos S, Radnidge P, Roberts BA, Scott JL. Direct, efficient, solvent-free synthesis of 2-aryl-1,2,3,4-tetrahydroquinazolines. Green Chem 2002;4:245.
- [10] Sinkkonen J, Zelenin KN, Potapov AA, Lagoda IV, Alekseyev VV, Pihlaja K. Ringchain tautomerism in 2-substituted 1,2,3,4-tetrahydroquinazolines A ¹H, ¹³C and ¹⁵N NMR study. Tetrahedron 2003;59:1939.
- [11] Mobinikhaledi A, Foroughifar N, Basaki N. Zeolite catalyzed efficient synthesis of perimidines at room temperature. Turk J Chem 2009;33:555.
- [12] Shaabani A, Maleki A, Mofakham H. Click reaction: highly efficient synthesis of 2,3-dihydroquinazolin-4(1H)-ones. Synth Commun 2008;38:3751.
- [13] Ried W, Wilk M. Einwirkung von Licht auf ω-Nitro-styrole Zusammenhang zwischen Polarisierbarkeit und Polymerisationsneigung beim Belichten von ω-Nitro-styrolen. Angew Chem 1953;65:398.